Home The Word Brain My Amedeo FAQ Privacy About   


C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.

  Bladder Cancer, February 2025

Free Subscription


Abstracts

Retrieve all available abstracts of the following 254 articles:
HTML format


 

Single Articles

  1. NAYYAR R
    Neoadjuvant chemotherapy for bladder cancer: Two decades on.
    Indian J Urol. 2025;41:1-2.
    PubMed    


  2. MURTHY V, Kashid SR, Pal M, Vadassery A, et al
    Prospective comparative study of quality of life in patients with bladder cancer undergoing cystectomy with ileal conduit or bladder preservation.
    BMJ Oncol. 2024;3:e000435.
    PubMed    
    Abstract available

  3. LI J, Jiang Y, Ma M, Wang L, et al
    Epithelial cell diversity and immune remodeling in bladder cancer progression: insights from single-cell transcriptomics.
    J Transl Med. 2025;23:135.
    PubMed    
    Abstract available

  4. FENG D, Kang X, Wang H, He Z, et al
    Photochemical bomb: Precision nuclear targeting to activate cGAS-STING pathway for enhanced bladder cancer immunotherapy.
    Biomaterials. 2025;318:123126.
    PubMed    
    Abstract available

  5. BELLMUNT J, Russell BM, Szabados B, Valderrama BP, et al
    Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma.
    Am Soc Clin Oncol Educ Book. 2025;45:e471912.
    PubMed    
    Abstract available

  6. YANG C, Wang W, Gao Y, Yin L, et al
    Sonodynamic Therapy by Reactive Oxygen Species Generation-Responsive Pseudo-Semiconducting Polymer Nanoparticles Combined with a Fibroblast Growth Factor Receptor Inhibitor for Enhancing Immunotherapy in Bladder Cancer.
    ACS Appl Mater Interfaces. 2025 Jan 30. doi: 10.1021/acsami.4c20545.
    PubMed    
    Abstract available

  7. JEONG IG, Yun SC, Ha HK, Kang SG, et al
    Urinary DNA Methylation Test for Bladder Cancer Diagnosis.
    JAMA Oncol. 2025 Jan 30. doi: 10.1001/jamaoncol.2024.6160.
    PubMed    
    Abstract available

  8. KELES A, Somun UF, Kose M, Arikan O, et al
    Exploring the influence of health and digital health literacy on quality of life and follow-up compliance in patients with primary non-muscle invasive bladder cancer: a prospective, single-center study.
    World J Urol. 2025;43:94.
    PubMed    
    Abstract available

  9. ABULSOUD AI, Aly SH, Abdel Mageed SS, Abdelmaksoud NM, et al
    Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.
    Med Oncol. 2025;42:56.
    PubMed    
    Abstract available

  10. SAOULI A, Zerda I, Elkhader K, Durand X, et al
    Utility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected patients: a systematic review.
    World J Urol. 2025;43:95.
    PubMed    
    Abstract available

  11. WONG CH, Ko IC, Leung DK, Yuen SK, et al
    A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Guerin Instillation for Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2025 Jan 28:S2588-9311(24)00296.
    PubMed    
    Abstract available

  12. MO Z, Gai S, Qin X, Meng D, et al
    Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein.
    Int J Biol Macromol. 2025 Jan 27:140438. doi: 10.1016/j.ijbiomac.2025.140438.
    PubMed    
    Abstract available

  13. GUDUGUNTLA A, Whish-Wilson T, Chandler L, Gyomber D, et al
    A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance.
    BJUI Compass. 2025;6:e468.
    PubMed    
    Abstract available

  14. KHAN MAAK, Sedgwick AJ, Sun Y, Vivian JP, et al
    Transcriptional signature of CD56(bright) NK cells predicts favourable prognosis in bladder cancer.
    Front Immunol. 2025;15:1474652.
    PubMed    
    Abstract available

  15. YANG L, Chen C, Wang Q, Zhuang Z, et al
    Development and Validation of a Competitive Risk Model in Elderly Patients with Transitional Cell Bladder Carcinoma.
    Med Sci Monit. 2025;31:e946332.
    PubMed    
    Abstract available

  16. CHEN Z, Chen X, Li D, Jian J, et al
    Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis.
    BMC Urol. 2025;25:19.
    PubMed    
    Abstract available

  17. YENTUR S, Dusunus YE, Ulus I, Kandirali IE, et al
    Does Bladder Outlet Obstruction Releated to Recurrence In Low Risk Ta Low Grade Non Muscle Invasive Bladder Cancer?
    Clin Genitourin Cancer. 2024;23:102296.
    PubMed    
    Abstract available

  18. HAMEED RS, Alhussain GSA, Almudhafar RH, Mahdi LH, et al
    Immunohistochemical evaluation of SOX-10 in patients with urinary bladder cancer.
    Wiad Lek. 2024;77:2481-2486.
    PubMed    
    Abstract available

  19. HAMEED RS, Almudhafar RH, Mahdi LH
    Immunohistochemical evaluation of GATA-3 in patients with urinary bladder cancer.
    Wiad Lek. 2024;77:2381-2387.
    PubMed    
    Abstract available

  20. ZHANG C, Yin H, Li T, Chen J, et al
    Identification of multicohort-based predictive signature for NMIBC recurrence reveals SDCBP as a novel oncogene in bladder cancer.
    Ann Med. 2025;57:2458211.
    PubMed    
    Abstract available

  21. CHEN Y, Luo F, Zhang T, Li J, et al
    Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy.
    Biol Proced Online. 2025;27:2.
    PubMed    
    Abstract available

  22. SAARINEN P, Jokelainen O, Ruotsalainen L, Ikonen E, et al
    The usage of the paris classification system in urine cytology in the diagnosis of non-muscle-invasive bladder cancer: a retrospective single-center study.
    Discov Oncol. 2025;16:95.
    PubMed    
    Abstract available

  23. AYDOGDU C, Brinkmann I, Casuscelli J
    [Erratum to: Novel systemic treatment options for advanced bladder cancer].
    Urologie. 2025 Jan 27. doi: 10.1007/s00120-024-02499.
    PubMed    


  24. EL AZZOUZI M, Addoum B, El Ahanidi H, Hassan I, et al
    Exploring the role of transcription factor TWIST1 in bladder cancer progression.
    Cancer Genet. 2025;292-293:44-48.
    PubMed    
    Abstract available

  25. SUZAN S, Ulus I, Hacibey I, Muslumanoglu AY, et al
    Predictive value of Bladder EpiCheck((R)) in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer.
    World J Urol. 2025;43:89.
    PubMed    
    Abstract available

  26. TANG J, Fan L, Huang T, Yang R, et al
    Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer.
    Front Immunol. 2025;15:1467527.
    PubMed    
    Abstract available

  27. SHEN C, Suo Y, Guo J, Su W, et al
    Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
    Front Immunol. 2025;15:1430583.
    PubMed    
    Abstract available

  28. SUN J
    Nanoparticle Therapies: Targeted Treatment for Bladder Cancer With Reduced Side Effects [Letter].
    Int J Nanomedicine. 2025;20:989-990.
    PubMed    


  29. SORNTHAI W, Teyateeti A, Taweemonkongsap T, Jitpraphai S, et al
    Preoperative myosteatosis and perioperative serum chloride levels predict 180 day major complications after radical cystectomy.
    Sci Rep. 2025;15:3184.
    PubMed    
    Abstract available

  30. CAO T, Zhu X, Guo C, Zhang H, et al
    Computed tomography-based nomogram for estimating progression-free survival probability in bladder cancer patients undergoing partial cystectomy.
    Abdom Radiol (NY). 2025 Jan 25. doi: 10.1007/s00261-024-04747.
    PubMed    
    Abstract available

  31. KOBYLKA P, Bakun P, Kuzminska J, Goslinski T, et al
    Insights into the Mode of Action of Novel Morpholinated Curcumin Derivatives Exhibiting Potent Antitumor Activity in Bladder Cancer Cells In Vitro.
    Molecules. 2025;30:295.
    PubMed    
    Abstract available

  32. PANAGIOTIS M, Ioannis G, Vasilleios K, Nikolaos P, et al
    New Trends and Future Perspectives in the Diagnosis of Urothelial Carcinoma: A Comprehensive Review of the Literature.
    Medicina (Kaunas). 2025;61:71.
    PubMed    
    Abstract available

  33. BELL SD, Quinn AE, Bajo A, Mayberry TG, et al
    Squamous Cell Bladder Cancer: A Rare Histological Variant with a Demand for Modern Cancer Therapeutics.
    Cancers (Basel). 2025;17:169.
    PubMed    
    Abstract available

  34. LAHOUD J, Okullo A, Rutherford C, Smith DP, et al
    Symptoms and Side Effects of Bacille Calmette-Guerin Therapy for Non-Muscle Invasive Bladder Cancer as Reported by Patients: A Systematic Review.
    Cancers (Basel). 2025;17:160.
    PubMed    
    Abstract available

  35. ISOBE H, Shimizu F, Ieda T, Nakamura S, et al
    Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain.
    Biomedicines. 2025;13:174.
    PubMed    
    Abstract available

  36. RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, et al
    Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies.
    Biomedicines. 2025;13:156.
    PubMed    
    Abstract available

  37. KWON WA, Seo HK, Song G, Lee MK, et al
    Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development.
    Biomedicines. 2025;13:86.
    PubMed    
    Abstract available

  38. TANAKA S, Murakami K, Sakatani T, Lee R, et al
    Effects of Different Voided Urine Sample Storage Time, Temperature, and Preservatives on Analysis with Multiplex Bead-Based Oncuria Bladder Cancer Immunoassay.
    Diagnostics (Basel). 2025;15:138.
    PubMed    
    Abstract available

  39. VAITHEGI R, Pai K, Calicut Kini Rao A, Monappa V, et al
    Clinicopathological study and molecular subtyping of muscle-invasive bladder cancer (MIBC) using dual immunohistochemical (IHC) markers.
    Diagn Pathol. 2025;20:10.
    PubMed    
    Abstract available

  40. XUE Z, Yan Y, Chen H, Mao H, et al
    Risk factors for lymphatic leakage following radical cystectomy and pelvic lymph node dissection in patients with muscle-invasive bladder cancer.
    World J Surg Oncol. 2025;23:23.
    PubMed    
    Abstract available

  41. WAN P, Ren Y, Deng H, Li H, et al
    CDCA4 promotes bladder cancer progression by JAK/STAT signaling pathway.
    J Cancer Res Clin Oncol. 2025;151:46.
    PubMed    
    Abstract available

  42. XU X, Xu J, Gao H, Sheng Z, et al
    Bibliometric analysis of photodynamic research in bladder cancer: trends and future directions.
    Photodiagnosis Photodyn Ther. 2025 Jan 22:104494.
    PubMed    
    Abstract available

  43. DENG X, Huang Y, Zhang J, Chen Y, et al
    Histone lactylation regulates PRKN-Mediated mitophagy to promote M2 Macrophage polarization in bladder cancer.
    Int Immunopharmacol. 2025;148:114119.
    PubMed    
    Abstract available

  44. HIRUMA K, Bilim V, Kazama A, Shirono Y, et al
    Acidic Microenvironment Enhances Cisplatin Resistance in Bladder Cancer via Bcl-2 and XIAP.
    Curr Issues Mol Biol. 2025;47:43.
    PubMed    
    Abstract available

  45. ANGELOPOULOS P, Markopoulos T, Lazarou L, Skolarikos A, et al
    Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece.
    Curr Oncol. 2024;32:18.
    PubMed    
    Abstract available

  46. CHANG KS, Chen ST, Lin WY, Hsu SY, et al
    Growth differentiation factor 15 is a glucose-downregulated gene acting as the cross talk between stroma and cancer cells of the human bladder.
    Am J Physiol Cell Physiol. 2025;328:C557-C573.
    PubMed    
    Abstract available

  47. BENJAMIN DJ, Mita AC
    FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies.
    Target Oncol. 2025;20:1-11.
    PubMed    
    Abstract available

  48. YANAGISAWA T, Mori K, Matsukawa A, Kawada T, et al
    Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.
    Target Oncol. 2025;20:57-69.
    PubMed    
    Abstract available

  49. LANGE F, Hartmann A, Eckstein M
    [Urinary bladder: tumor precursors and non-invasive carcinoma].
    Pathologie (Heidelb). 2025;46:21-26.
    PubMed    
    Abstract available

  50. MOHAMED KS, Desai K, El-Habashy D, Liu S, et al
    Pathological Extramural Venous Invasion in High-stage Urothelial Carcinoma of the Bladder has Shorter Locoregional Recurrence-free Survival.
    Int J Surg Pathol. 2025;33:41-48.
    PubMed    
    Abstract available

  51. REGMI A, Mehta M, Farooq AV, Turk TM, et al
    Localized Urinary Bladder Amyloidosis as Urothelial Cancer Mimicker: A Case Series Examining Cystoscopic, Histologic, and Cytologic Findings.
    Arch Pathol Lab Med. 2025;149:191-194.
    PubMed    
    Abstract available

  52. CHAMBERS M, Andre AT, Wright JL, Vakar-Lopez F, et al
    Outcome Analysis of a Series of Mixed-Grade, Non-muscle Invasive, Papillary Carcinomas of the Bladder.
    Int J Surg Pathol. 2025;33:19-25.
    PubMed    
    Abstract available

  53. KAYA F, Komek H, Dursun IH, Senses V, et al
    Pseudoprogression Shown on (18)F-FDG PET/CT After Pembrolizumab Treatment in a Case of Metastatic Bladder Cancer.
    Mol Imaging Radionucl Ther. 2025;34:70-72.
    PubMed    
    Abstract available

  54. SUN J, Li Z, Zhu X
    Prognostic role of prognostic nutritional index in patients with bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2025;14:1486389.
    PubMed    
    Abstract available

  55. FRANCO LS, Arunachalam S, Chauhan A, Kareff SA, et al
    Elevated expression of ANTXR1 gene in tumors is a poor prognostic biomarker for patients with bladder cancer.
    Front Mol Biosci. 2025;11:1520223.
    PubMed    
    Abstract available

  56. ZARRABI KK, Saxena A, Mouw KW, Koshkin VS, et al
    Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.
    Am Soc Clin Oncol Educ Book. 2025;45:e471924.
    PubMed    
    Abstract available

  57. LOPES GMM, Gimenez LGS, Santana DS, Cardoso RB, et al
    Pelvic Lymph Node Dissection Before Versus After Radical Cystectomy: A Systematic Review and Meta-Analysis.
    Int Braz J Urol. 2025;51:e20240490.
    PubMed    
    Abstract available

  58. HUANG P, Wang J, Yu Z, Lu J, et al
    Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion.
    Front Immunol. 2025;16:1537808.
    PubMed    
    Abstract available

  59. ALEM D, Garcia-Lavina CX, Garagorry F, Centurion D, et al
    Amyloids in bladder cancer hijack cancer-related proteins and are positive correlated to tumor stage.
    Sci Rep. 2025;15:4393.
    PubMed    
    Abstract available

  60. MONTORSI F, Rosiello G, Moschini M, Salonia A, et al
    Re: Akihiro Matsukawa, Takafumi Yanagisawa, Marcin Miszczyk, et al. Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies. Eur Urol Focus. In press. https://do
    Eur Urol Focus. 2025 Feb 4:S2405-4569(25)00016-1. doi: 10.1016/j.euf.2024.
    PubMed    


  61. POWLES T, Galsky MD, van der Heijden MS
    Perioperative Durvalumab in Bladder Cancer. Reply.
    N Engl J Med. 2025;392:619.
    PubMed    


  62. KOGA S, Mei L
    Perioperative Durvalumab in Bladder Cancer.
    N Engl J Med. 2025;392:618-619.
    PubMed    


  63. SUARTZ CV, Martinez LM, Silvestre MHL, Lima RD, et al
    Urachal Carcinomas: A Comprehensive Systematic Review and Meta-analysis.
    Int Braz J Urol. 2025;51:e20240665.
    PubMed    
    Abstract available

  64. VILLOLDO GM, Gonzalez MI, Faune AV, Molina RC, et al
    Multicenter Retrospective Registry Study on BCG Use in Non-Muscle Invasive Bladder Cancer in Latin America: BLATAM (Bladder Cancer in Latin America) Group.
    Int Braz J Urol. 2025;51:e20240615.
    PubMed    
    Abstract available

  65. ZHOU H, Liu Q, Chen M, Xie Y, et al
    Urease-Driven Janus Nanomotors for Dynamic Enrichment and Multiplexed Detection of Bladder Cancer MicroRNAs in Urine.
    ACS Sens. 2025 Feb 5. doi: 10.1021/acssensors.4c02996.
    PubMed    
    Abstract available

  66. ZHENG Y, Wang K, Wu C, Qin Y, et al
    COTI-2 suppresses the malignancy of bladder cancer by inducing apoptosis via the AMPK-mTOR signaling pathway.
    Iran J Basic Med Sci. 2025;28:240-246.
    PubMed    
    Abstract available

  67. PEIXOTO A, Ferreira D, Miranda A, Relvas-Santos M, et al
    Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.
    iScience. 2025;28:111758.
    PubMed    
    Abstract available

  68. SISAKHT MM, Gholizadeh F, Hekmatirad S, Mahmoudi T, et al
    Cost-reduction strategy to culture patient derived bladder tumor organoids.
    Sci Rep. 2025;15:4223.
    PubMed    
    Abstract available

  69. XU C, Dong Y, Pei D, Zhang X, et al
    Innovative logic "AND" gate gene circuits for bladder cancer treatment: preclinical study.
    Int J Surg. 2025 Feb 4. doi: 10.1097/JS9.0000000000002270.
    PubMed    
    Abstract available

  70. YAMAMOTO S, Yamasaki T, Matsue T, Yukimatsu N, et al
    [The Case of Solitary Adrenal Metastasis of Urothelial Carcinoma].
    Hinyokika Kiyo. 2025;71:5-8.
    PubMed    
    Abstract available

  71. KULKARNI GS, Black PC, Sridhar SS, Zlotta AR, et al
    2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer.
    Can Urol Assoc J. 2025;19:E1-E16.
    PubMed    


  72. LARSSON SC, Chen J, Ruan X, Li X, et al
    Genome-wide association study and Mendelian randomization analyses reveal insights into bladder cancer etiology.
    JNCI Cancer Spectr. 2025 Feb 3:pkaf014. doi: 10.1093.
    PubMed    
    Abstract available

  73. LUNA V, Wirth B, Valenzuela PR, Zens MS, et al
    Evaluation of Melanoma and Bladder Cancers in New Hampshire to Identify Registrar Training Needs.
    J Registry Manag. 2024;51:121-123.
    PubMed    
    Abstract available

  74. MITCHELL S, Vida C
    Journal of Registry Management Continuing Education Quiz-FALL 2024: EVALUATION OF MELANOMA AND BLADDER CANCERS IN NEW HAMPSHIRE TO IDENTIFY REGISTRAR TRAINING NEEDS.
    J Registry Manag. 2024;51:128.
    PubMed    
    Abstract available

  75. LIU Z, Zhang C, Xiao J, He Y, et al
    TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance.
    Theranostics. 2025;15:1966-1986.
    PubMed    
    Abstract available

  76. XU M, Chen S, Liu X, Luo Y, et al
    Best evidence for rehabilitation management of urinary incontinence in patients with bladder cancer following orthotopic neobladder reconstruction.
    Asia Pac J Oncol Nurs. 2024;12:100647.
    PubMed    
    Abstract available

  77. XU HR, Pang Z, Wang QZ, Ou-Yang S, et al
    S100A8 promotes the proliferation, migration and invasion in bladder cancer cells.
    J Cancer. 2025;16:1066-1077.
    PubMed    
    Abstract available

  78. EBRAHIMI P, Mahdavian A, Mousavinejad M, Ghadimi DJ, et al
    An Unusual Presentation of Bladder Carcinoma in a Visceral Hernia: A Case Report and Literature Review.
    Cancer Rep (Hoboken). 2025;8:e70128.
    PubMed    
    Abstract available

  79. HUANG M, Li H, Chen J, Li L, et al
    Blood lead levels and bladder cancer among US participants: NHANES 1999-2018.
    BMC Public Health. 2025;25:416.
    PubMed    
    Abstract available

  80. SCHOLTES MP, Akbarzadeh M, Galaras A, Nakauma-Gonzales JA, et al
    Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets.
    Cancer Lett. 2025 Jan 29:217506. doi: 10.1016/j.canlet.2025.217506.
    PubMed    
    Abstract available

  81. PAPPOT N, Maibom SL, Vejlgaard M, Joensen UN, et al
    Investigating the Potential to Offer Reproductive Organ Preserving Radical Cystectomy to More Female Bladder Cancer Patients.
    Clin Genitourin Cancer. 2025;23:102303.
    PubMed    
    Abstract available

  82. SCHNEIDEWIND L, Kiss B, Neumann T, Kranz J, et al
    Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC).
    J Cancer Res Clin Oncol. 2025;151:59.
    PubMed    
    Abstract available

  83. YANAGISAWA T, Mori K, Matsukawa A, Kawada T, et al
    Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis.
    Cancer Immunol Immunother. 2025;74:76.
    PubMed    
    Abstract available

  84. KAWAHARA T, Kandori S, Kojima T, Mathis BJ, et al
    Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study.
    BMC Res Notes. 2025;18:47.
    PubMed    
    Abstract available

  85. CONTRERAS-SANZ A, Negri GL, Reike MJ, Oo HZ, et al
    Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy.
    Nat Commun. 2025;16:1240.
    PubMed    
    Abstract available

  86. CHEN JF, Al-Ahmadie H
    Molecular Classification of Urothelial Carcinoma.
    Surg Pathol Clin. 2025;18:41-51.
    PubMed    
    Abstract available

  87. PAPKE DJ JR
    Mesenchymal Neoplasms of the Bladder and Male Genital Tract, including the Perineum and Scrotum.
    Surg Pathol Clin. 2025;18:229-247.
    PubMed    
    Abstract available

  88. BEAUCHAMP L, Indulkar S, Erak E, Salimian M, et al
    Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations.
    Surg Pathol Clin. 2025;18:175-189.
    PubMed    
    Abstract available

  89. XU J, Koch J, Schmidt C, Nientiedt M, et al
    Loss of YTHDC1 m(6)A reading function promotes invasiveness in urothelial carcinoma of the bladder.
    Exp Mol Med. 2025;57:118-130.
    PubMed    
    Abstract available

  90. SRISAJJAKUL S, Prapaisilp P, Bangchokdee S
    VI steps to achieve VI-RADS assessment.
    Eur J Radiol. 2025;183:111868.
    PubMed    
    Abstract available

  91. ARGOULON N, Morel H, Lanotte P, Ferreira M, et al
    [Antibioprophylaxis failure with BCG therapy for bladder neoplasia].
    Rev Mal Respir. 2025;42:75-80.
    PubMed    
    Abstract available

  92. SUZUKI S, Nagumo Y, Kojo K, Ikeda A, et al
    Variations in the diagnostic performance of transurethral resection of bladder tumor with photodynamic diagnosis according to surgical experience: A retrospective, single-center study.
    Photodiagnosis Photodyn Ther. 2025;51:104429.
    PubMed    
    Abstract available

  93. CHEN Z, Zhang T, Li W, Hu J, et al
    Single-cell RNA sequencing analysis reveals the dynamic changes in the tumor microenvironment during NMIBC recurrence.
    Apoptosis. 2025;30.
    PubMed    
    Abstract available

  94. FUKUHARA H, Nishimura T, Shimojo Y, Inoue K, et al
    Comparison of fluorescence intensity of protoporphyrin IX as observed on the screen of different cystoscopic systems.
    Photodiagnosis Photodyn Ther. 2025;51:104425.
    PubMed    
    Abstract available

  95. MURTHY V, Maitre P, Bakshi G, Pal M, et al
    Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2025;121:728-736.
    PubMed    
    Abstract available

  96. LE REUN E, Espenel S, Garcia MA, Girbovan AH, et al
    Image-Guided Brachytherapy for Pediatric Bladder and/or Prostate Rhabdomyosarcoma: Toward an Increased Personalization of Treatment.
    Int J Radiat Oncol Biol Phys. 2025;121:658-666.
    PubMed    
    Abstract available

  97. JUNG M, Kim B, Lee JS, Kim JY, et al
    KRT18 as a Novel Biomarker of Urothelial Papilloma while Evaluating Low-Grade Papillary Urothelial Neoplasms: Bi-Center Analysis.
    Pathobiology. 2025;92:28-39.
    PubMed    
    Abstract available

  98. GULER Y
    Clinical and pathological risk factors for tumour recurrence and upstaging in second TURBT for patients with NMIBC: a systematic review and meta-analysis.
    Aktuelle Urol. 2025;56:30-40.
    PubMed    
    Abstract available

  99. TSIMAFEYEU I, Gridneva Y, Sultanbaev A, Anzhiganova Y, et al
    Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.
    Cancer Med. 2025;14:e70636.
    PubMed    
    Abstract available

  100. KONISHI K, Fukumoto Y, Minoji T, Muranishi K, et al
    [A Case of Sigmoid Colon Cancer with Bladder Invasion Successfully Treated with Chemotherapy with mFOLFOX6+Cetuximab].
    Gan To Kagaku Ryoho. 2024;51:1797-1799.
    PubMed    
    Abstract available

  101. SUGIMOTO S, Paku M, Nagai K, Fukuchi N, et al
    [A Case of Rectal Cancer Resection with Total Cystectomy That Avoided a Double Stoma].
    Gan To Kagaku Ryoho. 2024;51:1758-1760.
    PubMed    
    Abstract available

  102. IIDA S, Ichikawa Y, Miyake M, Yanagi S, et al
    [A Case of Bladder Preservation by Neoadjuvant Chemotherapy for Sigmoid Colon Cancer with Bladder Invasion].
    Gan To Kagaku Ryoho. 2024;51:1434-1436.
    PubMed    
    Abstract available

  103. HAGIHARA K, Ikenaga M, Suzuki Y, Noma T, et al
    [Three Cases of Sigmoid Colon Cancer with Bladder Invasion That Were Treated with Neoadjuvant Chemotherapy, Allowing Radical Resection and Bladder Preservation].
    Gan To Kagaku Ryoho. 2024;51:1408-1410.
    PubMed    
    Abstract available

  104. FUJIMORI T, Kasagawa T, Ishii N, Kusashio K, et al
    [A Case of Bladder Metastasis from Invasive Ductal Carcinoma of the Breast-A Case Report].
    Gan To Kagaku Ryoho. 2024;51:1345-1347.
    PubMed    
    Abstract available

  105. XU X, Chen J, Bai M, Liu T, et al
    Plasma tsRNA Signatures Serve as a Novel Biomarker for Bladder Cancer.
    Cancer Sci. 2025 Feb 13. doi: 10.1111/cas.70003.
    PubMed    
    Abstract available

  106. DU G, Guan Y, Xie R, Li C, et al
    Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study.
    Urol Oncol. 2025 Feb 12:S1078-1439(25)00013.
    PubMed    
    Abstract available

  107. PYRGIDIS N, Hermans J, Keller P, Karatas D, et al
    Urinary Diversion and Quality of Life: A Six-Year Follow-Up Study of Bladder Cancer Surgery.
    Actas Urol Esp (Engl Ed). 2025 Feb 11:501699. doi: 10.1016/j.acuroe.2025.501699.
    PubMed    
    Abstract available

  108. DAVIES-TEYE BB, Siddiqui MM, Zhang X, Johnson A, et al
    Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With Urothelial Nonmetastatic Muscle-Invasive Bladder Cancer in the United States.
    Cancer Med. 2025;14:e70644.
    PubMed    
    Abstract available

  109. YU A, Bai Z, Wang Y, Luo Z, et al
    Impact of finasteride on modulating the risk and clinical outcomes of bladder cancer: insights from a comprehensive meta-analysis.
    Front Pharmacol. 2025;16:1471442.
    PubMed    
    Abstract available

  110. BADDAM S, Banka AV, Divity S, Sandesara M, et al
    Association between pioglitazone use and bladder cancer: A systematic review.
    Bladder (San Franc). 2024;11:e21200023.
    PubMed    
    Abstract available

  111. CAMPOBASSO D, Vezzini S, Buti S, Patera A, et al
    Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study.
    Bladder (San Franc). 2024;11:e21200019.
    PubMed    
    Abstract available

  112. LI J, Zhao L, Li L, Wang X, et al
    Urine exosomal lncRNAs as novel biomarkers for early diagnosis of bladder cancer based on microarray differential expression profiling.
    Int J Biol Markers. 2025 Feb 13:3936155251317551. doi: 10.1177/03936155251317551
    PubMed    
    Abstract available

  113. NIKULAINEN I, Salminen AP, Hogerman M, Seikkula H, et al
    Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes.
    Cancers (Basel). 2025;17:505.
    PubMed    
    Abstract available

  114. MELGAREJO-SEGURA MT, Zambudio-Munuera A, Arrabal-Polo MA, Lardelli-Claret P, et al
    Long-Term Outcomes of Intravesical Mitomycin C Administered via Electromotive Drug Administration or Conductive Chemo-Hyperthermia in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2025;17:453.
    PubMed    
    Abstract available

  115. IKHAPOH I, Atairu U, Reich AJ, Mantia CM, et al
    Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.
    J Clin Med. 2025;14:879.
    PubMed    
    Abstract available

  116. DEMIRCI A, Aydin H
    The effect of different adipose tissue measurements on clinical prognosis in bladder cancer patients undergoing radical cystectomy: preliminary results.
    Abdom Radiol (NY). 2025 Feb 13. doi: 10.1007/s00261-025-04838.
    PubMed    
    Abstract available

  117. LIN PY, Chang YF, Chen CC, Su LC, et al
    pH-Responsive Triplex DNA Nanoswitches: Surface Plasmon Resonance Platform for Bladder Cancer-Associated microRNAs.
    ACS Nano. 2025 Feb 12. doi: 10.1021/acsnano.4c16396.
    PubMed    
    Abstract available

  118. KRISHNAN S, Kanthaje S, Rekha PD, Mujeeburahiman M, et al
    Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer.
    Int Rev Cell Mol Biol. 2025;391:135-197.
    PubMed    
    Abstract available

  119. MARCQ G, Kassouf W, Roumiguie M, Pradere B, et al
    Oncological outcomes of patients with node positive disease following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma
    Actas Urol Esp (Engl Ed). 2025 Feb 10:501701. doi: 10.1016/j.acuroe.2025.501701.
    PubMed    
    Abstract available

  120. SALMAZO MIBF, Alonso JCC, de Arruda Camargo GC, de Oliveira G, et al
    Clinical and immunohistochemical effects of OncoTherad (MRB-CFI-1) nanoimmunotherapy on SERBP1, HABP4, CD44 and Ki-67 in BCG-unresponsive non-muscle invasive bladder cancer.
    Tissue Cell. 2025;93:102783.
    PubMed    
    Abstract available

  121. SEZGIN T, Ecer G, Yavuz C, Donmez S, et al
    Dermatological findings in bladder cancer: relationship between clinical and paraneoplastic syndromes.
    Arch Dermatol Res. 2025;317:389.
    PubMed    
    Abstract available

  122. BARALO B, Daniels PT, McIntire CA, Thirumaran R, et al
    Socioeconomic disparities in survival of patients with non-muscle invasive urothelial carcinoma.
    World J Urol. 2025;43:120.
    PubMed    
    Abstract available

  123. YAMASHITA T, Higashi M, Yamazaki M, Imada H, et al
    Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in Non-Muscle Invasive Bladder Cancer.
    Pathol Int. 2025 Feb 12. doi: 10.1111/pin.70002.
    PubMed    
    Abstract available

  124. DE JONG JJ, Proudfoot JA, Daneshmand S, Svatek RS, et al
    Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy.
    Eur Urol Open Sci. 2025;73:24-30.
    PubMed    
    Abstract available

  125. LI Q, Zhang Y, Su M, Song Y, et al
    Nucleotide variation in Foxp3 gene and prognosis of bladder cancer: a case-control study.
    Front Oncol. 2025;15:1506900.
    PubMed    
    Abstract available

  126. SHELLY S
    Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis.
    Front Immunol. 2025;16:1524200.
    PubMed    
    Abstract available

  127. VENEGONI C, Tortorella S, Caliendo A, Locatelli I, et al
    Urine-Stable Aptamer-Conjugated Gold Nanorods for the Early Detection of High-Grade Bladder Cancer Residual Disease.
    Adv Healthc Mater. 2025 Feb 11:e2403314. doi: 10.1002/adhm.202403314.
    PubMed    
    Abstract available

  128. SAKAGUCHI M, Maebayashi T, Sekino Y, Ishikawa H, et al
    Efficacy of curative radiotherapy for the treatment of elderly patients with muscle-invasive bladder cancer: a systematic review.
    BMC Urol. 2025;25:26.
    PubMed    
    Abstract available

  129. FILON M, Schmidt B
    New Treatment Options for Non-Muscle-Invasive Bladder Cancer.
    Am Soc Clin Oncol Educ Book. 2025;45:e471942.
    PubMed    
    Abstract available

  130. LIATSOS GD, Mariolis I, Hadziyannis E, Bamias A, et al
    Review of BCG immunotherapy for bladder cancer.
    Clin Microbiol Rev. 2025 Feb 11:e0019423. doi: 10.1128/cmr.00194.
    PubMed    
    Abstract available

  131. FALABELLA R, De Simone V, Crocetto F, Del Giudice F, et al
    New biomarkers for diagnosis of bladder cancer: a bibliometric analysis.
    Arch Ital Urol Androl. 2025 Feb 11:13396. doi: 10.4081/aiua.2025.13396.
    PubMed    
    Abstract available

  132. YANG B, Zeng X, Wang H, Feng J, et al
    Serum Matrix Metalloproteinases and Risk of Urologic Cancers: A Bidirectional Mendelian Randomization Study.
    Am J Mens Health. 2025;19:15579883241311229.
    PubMed    
    Abstract available

  133. NAKANO M, Gi M, Toyooka T, Suzuki S, et al
    Occupational health topics series on the effects of chemicals: epidemiological and toxicological risk assessments of ortho-toluidine on bladder cancer.
    J Occup Health. 2025 Feb 11:uiaf005. doi: 10.1093.
    PubMed    
    Abstract available

  134. MUNAVVIR M, M M, Khan A, Debashish GD, et al
    TAR-200: Investigational intravesical drug delivery system for bladder cancer.
    Urologia. 2025 Feb 10:3915603251319133. doi: 10.1177/03915603251319133.
    PubMed    
    Abstract available

  135. ACEDO-TERRADES A, Perera-Bel J, Nonell L
    The importance of data transformation in RNA-Seq preprocessing for bladder cancer subtyping.
    BMC Res Notes. 2025;18:61.
    PubMed    
    Abstract available

  136. LI Z, Wang Z, Liu Y, Yang L, et al
    IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment.
    Sci Rep. 2025;15:4874.
    PubMed    
    Abstract available

  137. ECKHART L, Rau S, Eckstein M, Stahl PR, et al
    Machine Learning Accurately Predicts Muscle Invasion of Bladder Cancer Based on Three miRNAs.
    J Cell Mol Med. 2025;29:e70361.
    PubMed    
    Abstract available

  138. NAITO Z, Wada M, Shichinohe T, Yoshida A, et al
    Internal Hernia Beneath the Obturator Nerve After Robot-Assisted Radical Cystectomy and Pelvic Lymphadenectomy: A Case Report With Literature Review.
    Asian J Endosc Surg. 2025;18:e70030.
    PubMed    
    Abstract available

  139. AL-NADER M, Krafft U, Hess J, Pullen L, et al
    Temporal patterns of major postoperative events after radical cystectomy: analysis of 90-day morbidity.
    World J Urol. 2025;43:111.
    PubMed    
    Abstract available

  140. EBNER B, Hirsch J, Holz A, Volz Y, et al
    Discrepancies between physician-assessed and patient-reported complications after cystectomy - a prospective analysis.
    World J Urol. 2025;43:115.
    PubMed    
    Abstract available

  141. BARDOWSKA K, Krajewski W, Kolodziej A, Koscielska-Kasprzak K, et al
    Evaluation of six novel biomarkers for predicting recurrence of non-muscle invasive bladder cancer after endoscopic resection- a prospective observational study.
    World J Urol. 2025;43:114.
    PubMed    
    Abstract available

  142. WANG JS, Shapiro JC, Orlando S, Al-Marayaty R, et al
    Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin.
    J Cancer Res Clin Oncol. 2025;151:73.
    PubMed    
    Abstract available

  143. HURLE R, Contieri R, Lazzeri M
    Comment to: "Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer".
    World J Urol. 2025;43:113.
    PubMed    


  144. FAN XP, Wang JR, Chen SY, Li XR, et al
    Mechanistic insights into PROS1 inhibition of bladder cancer progression and angiogenesis via the AKT/GSK3beta/beta-catenin pathway.
    Sci Rep. 2025;15:4748.
    PubMed    
    Abstract available

  145. ANNAPUREDDY D, Taylor JI, Kamat AM, O'Donnell MA, et al
    Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guerin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies.
    Eur Urol Focus. 2025 Feb 7:S2405-4569(25)00001-X. doi: 10.1016/j.euf.2025.
    PubMed    
    Abstract available

  146. MATSUKAWA A, Yanagisawa T, Miszczyk M, Kimura T, et al
    Reply to: Francesco Montorsi, Francesco Montorsi, Giuseppe Rosiello, Marco Moschini, Andrea Salonia, and Alberto Briganti's letter to the Editor re: Akihiro Matsukawa, Takafumi Yanagisawa, Marcin Miszczyk, et al. Trimodality Therapy Versus Radical Cys
    Eur Urol Focus. 2025 Feb 7:S2405-4569(25)00020-3. doi: 10.1016/j.euf.2025.
    PubMed    


  147. NUNEZ-RODRIGUEZ E, Lee BH, Cata JP
    Understanding regional anesthesia's impact on non-muscle invasive bladder cancer oncological outcomes.
    Reg Anesth Pain Med. 2025 Feb 8:rapm-2025-106433. doi: 10.1136/rapm-2025-106433.
    PubMed    


  148. ZHAO H, Lin N, Ho VWS, Liu K, et al
    Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment.
    Adv Sci (Weinh). 2025 Feb 7:e2414558. doi: 10.1002/advs.202414558.
    PubMed    
    Abstract available

  149. HSIEH CC, Li CC, Juan YS, Li WM, et al
    Impact of dialysis on intravesical recurrence and survival outcomes in upper tract urothelial cancer patients undergoing radical nephroureterectomy.
    Ren Fail. 2025;47:2458762.
    PubMed    
    Abstract available

  150. RODRIGUEZ PENARANDA N, di Bello F, Marmiroli A, Falkenbach F, et al
    Urinary Diversion Versus Adverse In-Hospital Outcomes After Radical Cystectomy.
    Ann Surg Oncol. 2025;32:2233-2240.
    PubMed    
    Abstract available

  151. JANGIR H, Narwal A, Adhikari SS, Batra A, et al
    Evaluation of Diagnostic Accuracy of the Paris System (TPS 2.0) in Urine Cytology Specimens: An Institutional Experience From a Large Cohort of a Tertiary Care Centre.
    Cytopathology. 2025;36:140-149.
    PubMed    
    Abstract available

  152. ZHANG X, Yun Y, Wang S, Wang M, et al
    The Value of Multi-directional High b-Value DWI in the Assessment of Muscular Invasion in Bladder Urothelial Carcinoma: In Comparison with VI-RADS.
    Acad Radiol. 2025;32:844-854.
    PubMed    
    Abstract available

  153. BEGAJ K, Sperr A, Jokisch JF, Clevert DA, et al
    Improved bladder diagnostics using multiparametric ultrasound.
    Abdom Radiol (NY). 2025;50:1240-1253.
    PubMed    
    Abstract available

  154. BHATT V, Malshy K, Homer A, Golijanin B, et al
    Investigating the association between blue light cystoscopy utilization and social determinants of health.
    Urologia. 2025;92:44-50.
    PubMed    
    Abstract available

  155. CHOUDHURY S, Ahmed S, Sasmal S, Patel P, et al
    En-bloc resection of non-muscle invasive urinary bladder tumors using low power Holmium laser-A new promise.
    Urologia. 2025;92:39-43.
    PubMed    
    Abstract available

  156. TAN WS, Ahmad A, Zhou Y, Nathan A, et al
    Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria.
    Eur Urol Oncol. 2025;8:87-93.
    PubMed    
    Abstract available

  157. CONTRERAS-SANZ A, Negri GL, Reike MJ, Oo HZ, et al
    Author Correction: Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy.
    Nat Commun. 2025;16:1855.
    PubMed    


  158. BOOPATHIRAJ N, Wagner IV, Powers R, Mashayekhi A, et al
    Chorioretinitis following Bacillus Calmette-Guerin Treatment for Bladder Cancer.
    Retin Cases Brief Rep. 2025 Feb 14. doi: 10.1097/ICB.0000000000001736.
    PubMed    
    Abstract available

  159. LI W, Luo P, Chen Q, Cheng L, et al
    Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs.
    Front Immunol. 2025;16:1518144.
    PubMed    
    Abstract available

  160. HUANG Z, Zhang T, Pan J, Zhang G, et al
    Transcriptomic Profiles for Elucidating Response of Bladder Intracavitary Hyperthermic Perfusion Chemotherapy in High-Risk Nonmuscular Invasive Bladder Cancer.
    Cancer Med. 2025;14:e70672.
    PubMed    
    Abstract available

  161. SHEN D, Yu X, Fan X, Liang Y, et al
    CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis.
    J Exp Clin Cancer Res. 2025;44:63.
    PubMed    
    Abstract available

  162. PLAGE H, Frericks A, Hofbauer S, Furlano K, et al
    GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis.
    BMC Urol. 2025;25:37.
    PubMed    
    Abstract available

  163. AKCA G, Ozturk C, Uzun H
    Ectopic prostate tissue presenting as a bladder tumor in a young man- a case report.
    BMC Urol. 2025;25:36.
    PubMed    
    Abstract available

  164. BOLL LM, Vazquez Montes de Oca S, Camarena ME, Castelo R, et al
    Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.
    Nat Commun. 2025;16:1213.
    PubMed    
    Abstract available

  165. HU K, Xiao M, Chen S, Huang Y, et al
    Innovative applications of natural polysaccharide polymers in intravesical therapy of bladder diseases.
    Carbohydr Polym. 2025;354:123307.
    PubMed    
    Abstract available

  166. ZEMLA J, Verdier C, Luty M, Pabijan J, et al
    Mechanical modulation of docetaxel-treated bladder cancer cells by various changes in cytoskeletal structures.
    J Mech Behav Biomed Mater. 2025;165:106952.
    PubMed    
    Abstract available

  167. WANG K, Li L, Liang G, Xiao H, et al
    Sonodynamic activated nanoparticles with Glut1 inhibitor and cystine-containing polymer stimulate disulfidptosis for improved immunotherapy in bladder cancer.
    Biomaterials. 2025;319:123178.
    PubMed    
    Abstract available

  168. SMANI S, DuBois J, Zhao K, Sutherland R, et al
    Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.
    Curr Oncol Rep. 2025 Feb 20. doi: 10.1007/s11912-025-01645.
    PubMed    
    Abstract available

  169. FIALA O, Buti S, Fujita K, de Liano AG, et al
    Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2(EV) study.
    Clin Exp Metastasis. 2025;42:18.
    PubMed    
    Abstract available

  170. WANG Y, Zhong K, Tan X, Zhou Q, et al
    Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma: A Real-World Study.
    Cancer Med. 2025;14:e70661.
    PubMed    
    Abstract available

  171. UNSWORTH-WHITE S, Humayun-Zakaria N, Bryan RT
    Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2025;14:1-3.
    PubMed    


  172. JI J, Lai CH, Ni R, Wang M, et al
    Efficacy of cystectomy in single-site oligometastatic bladder cancer: a Surveillance, Epidemiology, and End Results (SEER) study of 1,381 patients.
    Transl Androl Urol. 2025;14:81-90.
    PubMed    
    Abstract available

  173. SEO HK, Jung EH, Song G
    Long-term efficacy of two sequential induction courses of Bacillus Calmette-Guerin in patients with high-risk non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2025;14:4-7.
    PubMed    


  174. XU MY, Sun JX, Xiang YX, Hua ZJ, et al
    A novel nomogram for predicting post-operative recurrence for patients with intermediate and high-risk non-muscle invasive bladder cancer after thulium laser resection of bladder tumors or conventional transurethral resection of bladder tumors followe
    Transl Androl Urol. 2025;14:91-102.
    PubMed    
    Abstract available

  175. KUMBHAM S, Md Mahabubur Rahman K, Foster BA, You Y, et al
    A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.
    ACS Pharmacol Transl Sci. 2025;8:286-307.
    PubMed    
    Abstract available

  176. VERGHOTE F, Rammant E, Dirix P, Van Praet C, et al
    Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial-Results of Secondary Endpoints.
    Eur Urol Focus. 2025 Feb 18:S2405-4569(25)00042.
    PubMed    
    Abstract available

  177. JOHNSON BA 3RD, Parimi V, Kamanda S, Corney DC, et al
    Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells.
    J Pathol Clin Res. 2025;11:e70021.
    PubMed    
    Abstract available

  178. MANSOURABADI Z, Assarehzadegan MA, Mehdipour F, Ariafar A, et al
    Neutrophil Extracellular Traps and Reactive Oxygen Species: Predictors of Prognosis in Bladder Cancer.
    Immunol Lett. 2025 Feb 17:106991. doi: 10.1016/j.imlet.2025.106991.
    PubMed    
    Abstract available

  179. HO CH, Fan CK, Chu YC, Liu SP, et al
    Effects of pterostilbene on inducing apoptosis in normal bladder and bladder cancer cells.
    Tissue Cell. 2025;94:102794.
    PubMed    
    Abstract available

  180. LIU G, Hong T, Liu X, Lin X, et al
    Predictive role of lactylation-related gene signature in the prognosis and immunotherapy response in bladder cancer.
    Arch Ital Urol Androl. 2025 Feb 17:13516. doi: 10.4081/aiua.2025.13516.
    PubMed    
    Abstract available

  181. OU Q, Xie W, Yu Y, Ou B, et al
    Contrast-enhanced ultrasound enables precision diagnosis of preoperative muscle invasion in bladder cancer: a prospective study.
    MedComm (2020). 2025;6:e70106.
    PubMed    
    Abstract available

  182. WU L, He S, He Y, Wang X, et al
    Retracted: IC-2 Suppresses Proliferation and Induces Apoptosis of Bladder Cancer Cells via the Wnt/beta-Catenin Pathway.
    Med Sci Monit. 2025;31:e948581.
    PubMed    
    Abstract available

  183. BURK L, Bender A, Wright MN
    High-Dimensional Variable Selection With Competing Events Using Cooperative Penalized Regression.
    Biom J. 2025;67:e70036.
    PubMed    
    Abstract available

  184. LIU P, Cai L, Que H, Jiang M, et al
    Evaluating biparametric MRI for diagnosing muscle-invasive bladder cancer with variant urothelial histology: a multicenter study.
    Cancer Imaging. 2025;25:15.
    PubMed    
    Abstract available

  185. TAHA SM, Abdallah AA, Osman YM, Taha MM, et al
    Outcomes of radical cystectomy in a resource-limited setting: a pilot study.
    BMC Urol. 2025;25:31.
    PubMed    
    Abstract available

  186. JI J, Wang F, Lai CH, Wang M, et al
    Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy.
    Sci Rep. 2025;15:5977.
    PubMed    
    Abstract available

  187. WEI W, Li H, Tian S, Zhang C, et al
    Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling.
    J Clin Invest. 2025 Feb 18:e186648. doi: 10.1172/JCI186648.
    PubMed    
    Abstract available

  188. LIN L, He M, Zeng Y, Ni X, et al
    Case report: Successful treatment of hyperbaric oxygen for radiation-induced hemorrhagic cystitis in a 95-year-old patient with bladder cancer.
    Front Oncol. 2025;15:1410148.
    PubMed    
    Abstract available

  189. WU J, Deng Z, Lei X, Xu Z, et al
    Prognostic evaluation of non-muscle invasive bladder cancer with P-CRP and its nomogram.
    Front Oncol. 2025;15:1406585.
    PubMed    
    Abstract available

  190. ZHANG L, Zhang L, Shi Z, Mi Y, et al
    Transcriptional Regulation of NUPR1 by MYH11 Activates PI3 K/AKT and Promotes Bladder Cancer Progression Through Ferroptosis and M2 Polarization of Macrophages.
    Technol Cancer Res Treat. 2025;24:15330338241305434.
    PubMed    
    Abstract available

  191. ZUO Y, Ren D, He H, Huang C, et al
    CircST6GALNAC6 Inhibits Glycolysis of Bladder Cancer by Regulating PRKN/HK1 Signaling Pathway.
    Mol Carcinog. 2025 Feb 17. doi: 10.1002/mc.23894.
    PubMed    
    Abstract available

  192. GAO S, Liu C, Mao L, Chen Y, et al
    Cancer Cell and Cancer-Associated Fibroblast Communication-Mediated Molecular Subtypes Portray Non-Inflamed Tumor Microenvironment and Guide the Precision Treatment of Bladder Cancer.
    Adv Biol (Weinh). 2025 Feb 17:e2400434. doi: 10.1002/adbi.202400434.
    PubMed    
    Abstract available

  193. AKBULUT I, Odemis I, Atalay S
    Analysis of local and systemic side effects of bacillus Calmette-Guerin immunotherapy in bladder cancer: a retrospective study in Turkiye.
    PeerJ. 2025;13:e18870.
    PubMed    
    Abstract available

  194. SRECKOVIC M, Backovic D, Dugandzija T, Dragicevic I, et al
    EXPOSURE TO ARSENIC IN DRINKING WATER AND RISK OF BLADDER CANCER.
    Acta Clin Croat. 2024;63:55-64.
    PubMed    
    Abstract available

  195. ZHANG H, Li J, Zhang Q, Liu Y, et al
    Comparison of neoadjuvant chemotherapy and combined chemotherapy with immunotherapy for muscle-invasive bladder cancer: a propensity score-matched analysis.
    Am J Transl Res. 2025;17:125-143.
    PubMed    
    Abstract available

  196. RAMOA OLIVEIRA AS, Afonso R, Macedo E, Silverio B, et al
    Systemic Bacillus Calmette-Guerin (BCG) Infection in a Patient With Non-Muscle-Invasive Bladder Cancer: A Case Report.
    Cureus. 2025;17:e77558.
    PubMed    
    Abstract available


  197. RETRACTION: CAB39 Modulates Epithelial-Mesenchymal Transition Through NF-kappaB Signaling Activation, Enhancing Invasion, and Metastasis in Bladder Cancer.
    Environ Toxicol. 2025 Feb 16. doi: 10.1002/tox.24498.
    PubMed    
    Abstract available

  198. TAKASHIMA J, Kobayashi H, Koizumi A, Shigehara F, et al
    [A Case of Laparoscopic Sigmoidectomy for Sigmoid Colon Cancer after Open Total Cystectomy].
    Gan To Kagaku Ryoho. 2025;52:76-78.
    PubMed    
    Abstract available

  199. YIN C, Liufu C, Ye S, Zhu T, et al
    Tumor-derived exosomal KPNA2 activates fibroblasts and interacts with KIFC1 to promote bladder cancer progression, a process inhibited by miR-26b-5p.
    Cell Mol Biol Lett. 2025;30:20.
    PubMed    
    Abstract available

  200. MIYAKE M, Nishimura N, Oda Y, Miyamoto T, et al
    Comparison of Post-Radical Cystectomy Renal Function and Ileal Conduit-Related Complications Between Extracorporeal and Robot-Assisted Intracorporeal Urinary Diversion: A Single-Center Experience.
    Asian J Endosc Surg. 2025;18:e70033.
    PubMed    
    Abstract available

  201. GERALD T, Woldu SL, Halstuch D, Ber Y, et al
    Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure.
    Urol Oncol. 2025 Feb 15:S1078-1439(25)00014.
    PubMed    
    Abstract available

  202. TAN C, Li C, Ge R, Zhang W, et al
    Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization.
    Cancer Cell Int. 2025;25:48.
    PubMed    
    Abstract available

  203. CHIANG CH, Yang JD, Liu WL, Chang FY, et al
    Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF-kappaB signaling inactivation.
    Cancer Cell Int. 2025;25:47.
    PubMed    
    Abstract available

  204. AIRES I, Parada B, Ferreira R, Oliveira PA, et al
    Recent animal models of bladder cancer and their application in drug discovery: an update of the literature.
    Expert Opin Drug Discov. 2025 Feb 17:1-21. doi: 10.1080/17460441.2025.2465373.
    PubMed    
    Abstract available

  205. LEE MH, Wu HC, Chen WC, Chen YF, et al
    IC/BPS is not associated with bladder cancer: a nationwide propensity score matched cohort study in Taiwan.
    World J Urol. 2025;43:123.
    PubMed    
    Abstract available

  206. TSUBOI I, Matsukawa A, Kardoust Parizi M, Schulz RJ, et al
    Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2025 Jan 23:102306. doi: 10.1016/j.clgc.2025.102306.
    PubMed    
    Abstract available

  207. ANDREA GROSSO A, Cadenar A, Pillozzi S, Carli G, et al
    Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review.
    Actas Urol Esp (Engl Ed). 2025 Feb 12:501717. doi: 10.1016/j.acuroe.2025.501717.
    PubMed    
    Abstract available

  208. FERNANDES C, Baptista I, Manso M, Ferreira C, et al
    The oncological impact of complete transurethral resection before neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Actas Urol Esp (Engl Ed). 2025 Feb 12:501712. doi: 10.1016/j.acuroe.2025.501712.
    PubMed    
    Abstract available

  209. ZHU W, Wu X, Zhao Z, Zhou M, et al
    In Vivo Time-Resolved Single-Cell RNA-Seq Reveals Chemotherapy-Induced Transcriptional Dynamics in Tumor Infiltrating Lymphocytes.
    Anal Chem. 2025;97:3438-3448.
    PubMed    
    Abstract available

  210. HOU J, Niu Y, Yan J, Tian J, et al
    Non-invasive diagnosis for urothelial carcinoma using a dual-target DNA methylation biomarker panel.
    Clin Chim Acta. 2025;569:120164.
    PubMed    
    Abstract available

  211. NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
    Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma.
    Int J Clin Oncol. 2025;30:524-531.
    PubMed    
    Abstract available

  212. HASALIGIL A, Munro V, Strunz-McKendry T, Wang-Silvanto J, et al
    Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain.
    Future Oncol. 2025;21:569-578.
    PubMed    
    Abstract available

  213. EINERHAND SMH, van der Heijden MS
    Advancements in the front-line treatment of metastatic urothelial carcinoma.
    Eur Urol Focus. 2024;10:972-974.
    PubMed    
    Abstract available

  214. ROBESTI D, Moschini M, Pio Tenace N, Burgio G, et al
    The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder.
    Eur Urol Focus. 2024;10:1043-1048.
    PubMed    
    Abstract available

  215. DOS SANTOS PRM, da Silva Gomes PR, Romao P, Maluf FC, et al
    Enhancing RECK Expression Through miR-21 Inhibition: A Promising Strategy for Bladder Carcinoma Control.
    Biochem Genet. 2025;63:817-831.
    PubMed    
    Abstract available

  216. BEEREN I, Meijer H, van der Heijden AG, Aben KKH, et al
    Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jan 25. doi: 10.1111/bju.16665.
    PubMed    
    Abstract available


  217. Advances in the management of high-risk localised muscle invasive bladder cancer.
    BJU Int. 2025;135:364-365.
    PubMed    


  218. TILLU N, Ben-David R, Skokic V, Rich JM, et al
    Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 20. doi: 10.1111/bju.16686.
    PubMed    
    Abstract available

  219. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
    Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 18. doi: 10.1111/bju.16675.
    PubMed    
    Abstract available

  220. STRUCK JP, Moharam N, Leitenberger A, Weber J, et al
    An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.
    BJU Int. 2025;135:446-455.
    PubMed    
    Abstract available

  221. BEN-DAVID R, Lidagoster S, Geduldig J, Kolanukuduru KP, et al
    Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes.
    BJU Int. 2025;135:473-480.
    PubMed    
    Abstract available

  222. GARCIA-DEL-MURO X, P Valderrama B, Medina-Colmenero A, Etxaniz O, et al
    Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
    Clin Cancer Res. 2025;31:659-666.
    PubMed    
    Abstract available

  223. STENZL A
    The Cost of Bladder Cancer: What Can Be Done?
    Eur Urol. 2025 Jan 28:S0302-2838(25)00017-X. doi: 10.1016/j.eururo.2025.
    PubMed    


  224. RAGGI D, Chakrabarti D, Green H, Huddart RA, et al
    Re: Standard or Extended Lymphadenectomy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Jan 27:S0302-2838(25)00020-X. doi: 10.1016/j.eururo.2025.
    PubMed    


  225. LI R, Linscott J, Catto JWF, Daneshmand S, et al
    FGFR Inhibition in Urothelial Carcinoma.
    Eur Urol. 2025;87:110-122.
    PubMed    
    Abstract available

  226. HURLE R, Bernardini B, Contieri R, Lazzeri M, et al
    Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life.
    Eur Urol. 2025 Feb 3:S0302-2838(25)00022-3. doi: 10.1016/j.eururo.2025.
    PubMed    


  227. ECKE TH, Le Calvez-Kelm F, van Poppel H
    Why We Need More Attention on Bladder Cancer: Establishing Policy Recommendations for Health Care Professionals and Politicians.
    Eur Urol. 2025 Feb 19:S0302-2838(25)00095-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    Abstract available

  228. YAMAMOTO A, Kawashima A, Uemura T, Nakano K, et al
    A novel mouse model of upper tract urothelial carcinoma highlights the impact of dietary intervention on gut microbiota and carcinogenesis prevention despite carcinogen exposure.
    Int J Cancer. 2025;156:1439-1456.
    PubMed    
    Abstract available

  229. WAN X, Wang D, Zhang X, Xu M, et al
    Unleashing the power of urine?based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review).
    Int J Oncol. 2025;66:18.
    PubMed    
    Abstract available

  230. MIYAKE M
    Editorial Comment from Dr Miyake to alpha1-blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2025 Jan 28. doi: 10.1111/iju.15687.
    PubMed    


  231. HARA S, Fukuokaya W, Miki J, Taoka R, et al
    Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2025 Feb 5. doi: 10.1111/iju.70005.
    PubMed    
    Abstract available

  232. SHINDO T, Ueki Y, Muranaka I, Kobayashi G, et al
    Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer.
    Int J Urol. 2025 Feb 13. doi: 10.1111/iju.70009.
    PubMed    
    Abstract available

  233. CONTIERI R, Guigui A, Gondran-Tellier B, Basile G, et al
    Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European study.
    Int Urol Nephrol. 2025 Feb 11. doi: 10.1007/s11255-025-04416.
    PubMed    
    Abstract available

  234. CHEN CC, Yen TH, Li JR, Chen CJ, et al
    Artificial intelligence algorithms enhance urine cytology reporting confidence in postoperative follow-up for upper urinary tract urothelial carcinoma.
    Int Urol Nephrol. 2025;57:801-808.
    PubMed    
    Abstract available

  235. FAN H, Chen W, Guo W, Han J, et al
    Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years.
    Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04413.
    PubMed    
    Abstract available

  236. STROJNY Z, Kawka E, Strojny M, Kucz-Chrostowska A, et al
    Exploring the impact of chronotype, chrononutrition and lifestyle on bladder cancer.
    Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04371.
    PubMed    
    Abstract available

  237. KAMAT AM, Frankel P
    Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?
    J Clin Oncol. 2025 Feb 5:JCO2402482. doi: 10.1200/JCO-24-02482.
    PubMed    


  238. HEER R, Boaz RJ, Tan WS, Gravestock P, et al
    Letter: Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2025 Feb 7:101097JU0000000000004431. doi: 10.1097/JU.0000000000004431.
    PubMed    


  239. KHENE ZE, Bhanvadia R, Attia S, Ito W, et al
    Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naive Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer.
    J Urol. 2025 Feb 10:101097JU0000000000004472. doi: 10.1097/JU.0000000000004472.
    PubMed    
    Abstract available

  240. HOLZBEIERLEIN JM
    Reply: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2025 Feb 10:101097JU0000000000004452. doi: 10.1097/JU.0000000000004452.
    PubMed    


  241. CHEN H, Wu M, Chen M
    Prognostic Significance of Albumin-Globulin Ratio in Urachal Carcinoma.
    Urol Int. 2025;109:8-17.
    PubMed    
    Abstract available

  242. LIU R, Zhang Y, Zhou Z
    Patient-Derived Bladder Cancer Organoids: Model Construction and Drug Sensitivity Testing.
    Urol Int. 2025 Feb 10:1-16. doi: 10.1159/000543983.
    PubMed    
    Abstract available

  243. KUMAR S, Razaqi N, Mehta R, Sah R, et al
    Comment on "Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis".
    Urology. 2025 Jan 29:S0090-4295(25)00008-1. doi: 10.1016/j.urology.2025.
    PubMed    


  244. MICHAEL PD, Campbell RA
    Editorial comment on "A comparison between intravesical Gemcitabine plus Docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes".
    Urology. 2025 Feb 10:S0090-4295(25)00139-6. doi: 10.1016/j.urology.2025.
    PubMed    


  245. TRIPATHY R, Kumar L
    Editorial Comment on "A comparison between intravesical Gemcitabine plus Docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes".
    Urology. 2025 Feb 19:S0090-4295(25)00176-1. doi: 10.1016/j.urology.2025.
    PubMed    


  246. LI P, Jing S, Kang Y, Feng B, et al
    Clinical outcomes of nephroureterectomy with bladder cuff excision or radical cystectomy for distal ureteral carcinoma invaded muscle of the ureteral orifice.
    BMC Cancer. 2025;25:221.
    PubMed    
    Abstract available

  247. FURUKAWA J, Kakei Y, Murakami S, Kita H, et al
    Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.
    BMC Cancer. 2025;25:195.
    PubMed    
    Abstract available

  248. LI KP, Wan S, Wang CY, Chen SY, et al
    Multi-omics analysis reveals the impact of YAP/TEAD4-mediated EIF5A1 expression on mitochondrial apoptosis and bladder cancer progression.
    BMC Cancer. 2025;25:234.
    PubMed    
    Abstract available

  249. CAI J, Yan Z, Zhong Y, Li Y, et al
    Small non-coding RNA profiling in patients with non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:319.
    PubMed    
    Abstract available

  250. ZHENG Z, Dai F, Liu J, Zhang Y, et al
    Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer.
    BMC Cancer. 2025;25:310.
    PubMed    
    Abstract available

  251. YAN L, Liang H, Qi T, Deng D, et al
    Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    BMC Cancer. 2025;25:297.
    PubMed    
    Abstract available

  252. WANG C, Li K, Huang R, Wan S, et al
    Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer.
    BMC Cancer. 2025;25:271.
    PubMed    
    Abstract available

  253. LI Z, Wang Z, Wu J, Zhang F, et al
    Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients.
    BMC Cancer. 2025;25:268.
    PubMed    
    Abstract available

  254. ZHANG C, Weimann A, Stolzenburg JU, Neuhaus J, et al
    Notch2/3-DLL4 interaction in urothelial cancer cell lines supports a tumorigenic role of Notch signaling pathways in bladder carcinoma.
    PLoS One. 2025;20:e0317709.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;